Douglas Mayers News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Douglas Mayers. Real-time updates on events, politics, business and more.

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

June 25, 2022

New data presented in two separate oral presentations at the European Association for the Study of the Livers International Liver Congress 2022 (EASL ILC...

United States Douglas Mayers Istituto Nazionale Genetica Molecolare Luca Guidotti World Health Organization Antios Therapeutics Inc

Source: prnewswire.com

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies

March 30, 2022

/PRNewswire/ -- Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic...

Soult Ukpyolsi South Korea United States Katherine Squires Douglas Mayers World Health Organization

Source: prnewswire.com

Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference

October 7, 2021

/PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic...

Douglas Mayers Gregory Mayes Prnewswire Antios Therapeutics Inc Antios Therapeutics Inc Chief Executive Officer Chief Medical Officer

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Douglas Mayers News Today

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies

Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference

Explore More Categories